Ennovabio Pharmaceuticals Files IPO Prospectus: Advancing a Multi-Target, Multi-Disease Pipeline Guided by Bioinformatics for Precision Drug Discovery

In recent years, several well-known multinational pharmaceutical companies have adjusted their R&D strategies in China, reducing or suspending early-stage research activities in the country.

In stark contrast, focusing on new drug R&D has become an irreversible trend for Chinese pharmaceutical companies. The emergence of local innovative drug developers, such as Jiangsu Hengrui Pharmaceuticals and BeiGene, has sparked a wave of innovation in drug development. A large number of R&D professionals are choosing to start their own ventures, making small R&D firms an important force in China’s innovative drug development landscape.

In 2017, Dr. Jiang Lei and Dr. Shou Jianyong, both former employees of Novartis, co-founded Shanghai Yinuo Pharmaceutical Co., Ltd. (hereinafter referred to as “Yinuo Pharmaceutical”), focusing on the research and development of Class 1.1 new drugs and committing to source innovation, with the aim of providing maximum therapeutic value to patients in China.Currently, the company has completed nearly RMB 100 million in Series A financing.

It is understood that Yinuo Pharmaceutical’s R&D pipeline covers oncology, autoimmune diseases, inflammatory diseases, and diabetic complications. Among these, the company has made substantial progress in its project targeting diabetic eye disease, with clinical trials expected to be initiated in both China and the United States next year.

Yinuo Pharmaceutical currently has six R&D projects in its pipeline. Dr. Shou Jianyong, the company’s founder and Chief Scientific Officer, stated, “Startups have limited resources and weaker risk resilience; therefore, extreme caution is required when designing the R&D pipeline and formulating R&D strategies.”

Dr. Shou shared with VCBeat some insights from Yinuo Pharmaceutical regarding its R&D strategy and pipeline layout.

R&D projects must address unmet clinical needs.Shanghai Yinuo Pharmaceutical Co., Ltd. is driven by the vision of addressing unmet clinical needs to deliver maximum therapeutic value to patients. The company focuses on high-prevalence conditions in the Chinese population, including diabetic complications, cancer, autoimmune diseases, and inflammatory disorders. These diseases currently lack effective treatment options, representing significant unmet clinical needs.

Taking diabetes complications as an example, China has an estimated 116 million patients with diabetes, making it the country with the highest prevalence of diabetes worldwide. Various complications caused by hyperglycemia, such as diabetic foot, cardiovascular and cerebrovascular diseases, renal failure, and blindness, are the leading causes of death among diabetic patients. The pathogenesis of diabetes complications has long been complex, and existing therapeutic drugs fall far short of meeting clinical needs.

Dr. Shou stated, “The substantial clinical demand also implies a large patient population and faster enrollment in clinical studies, which can facilitate the rapid and steady advancement of projects, potentially accelerating the completion of proof of concept.”

The R&D pipeline layout should avoid homogeneous competition.Dr. Shou remarked, “Many domestic start-ups in new drug development suffer from serious homogenization in their R&D strategies and pipeline layouts. Companies tend to cluster around similar disease areas and identical targets, leading to significant resource waste, hindering corporate growth, and adversely affecting the healthy development of China’s innovative drug R&D ecosystem.” Therefore, Shanghai Yinuo Pharmaceutical Co., Ltd. has not confined itself to a single disease area; instead, it focuses on multiple targets and diverse disease fields to mitigate R&D risks.

Leveraging Bioinformatics to Guide New Drug Development.Dr. Shou stated that the relationship between diseases and targets is not a simple one-to-one correspondence; rather, they form an intricate network of associations, where one target may correspond to multiple diseases, and vice versa. Shanghai Yinuo Pharmaceutical Co., Ltd. employs bioinformatics to guide new drug development. Through systematic bioinformatic analysis, the company identifies key nodes in signaling pathways within complex disease networks as therapeutic targets, thereby selecting appropriate disease areas for drug development.

The primary advantage of bioinformatics lies in its ability to manage and analyze large volumes of biological and medical data in a low-cost, high-throughput manner, with a focus on further extracting valuable information related to drug efficacy, mechanisms of action, and side effects.

“Traditional drug development is characterized by high costs, long cycles, and high failure rates. Bioinformatics can help researchers gain unique insights during the drug discovery process, with the aim of improving R&D efficiency and reducing risks,” said Dr. Shou.

Dr. Shou has consistently emphasized the application of bioinformatics. He candidly acknowledged that many of the projects he previously led or participated in benefited significantly from bioinformatics guidance, including studies on the molecular mechanisms of the tumor microenvironment, epigenetic regulation in oncology and regenerative medicine, and combination drug strategies for metabolic diseases.

In addition, nearly 40% of Shanghai Yinuo Pharmaceutical Co., Ltd.’s employees hold doctoral degrees, while 80% possess master’s degrees or higher. Eighty-five percent of the staff have backgrounds in major international corporations, and many core team members have overseas study and work experience. The entire team boasts extensive experience in drug R&D and has established its own bioinformatics department. This robust team structure provides strong support for Yinuo Pharmaceutical’s bioinformatics-driven new drug development across multiple targets and therapeutic areas.

Currently, Shanghai Yinuo Pharmaceutical Co., Ltd. has made substantial progress in its project targeting diabetic eye disease and is expected to file for clinical trial approvals in both China and the United States next year.

Diabetic eye disease is a leading cause of blindness, affecting approximately 27% of patients with diabetes. Due to the complex pathogenesis of this condition, there are currently no effective treatments other than laser surgery and intravitreal injections of anti-angiogenic drugs.Shanghai Yinuo Pharmaceutical Co., Ltd. is developing a therapy for diabetic eye disease by targeting a novel mechanism that closely aligns with the complex pathogenesis of the condition; currently, no drugs targeting this specific pathway have been approved globally.

Dr. Shou stated, “This target is a node molecule in a key signaling pathway and is also suitable for developing drugs targeting other diabetic complications, making it a highly promising target.” Additionally, other projects at Shanghai Yinuo Pharmaceutical Co., Ltd. are proceeding in an orderly manner, with several projects nearing the selection of preclinical candidate (PCC) compounds.

Next, Yinuo Pharmaceutical will accelerate the R&D project for a novel drug targeting diabetic eye disease and conduct proof-of-concept studies in humans. The company will also further optimize its drug development pipeline to ensure sustainable growth. “We aim to have at least one project enter clinical trials each year, establishing a virtuous cycle.”

“We will build corresponding teams based on the company’s strategic needs at different stages, including teams for product industrialization, clinical development, and marketing, to better maximize product value and ensure the company’s sustainable development,” said Dr. Shou.

With the introduction of the Marketing Authorization Holder (MAH) system and China’s accession to the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), policy support for innovative drug R&D has been steadily increasing, drawing a surge of capital and talent into the field. “This is an excellent time for developing innovative drugs,” remarked Dr. Shou. “However, with the finalization of the ‘4+7’ centralized procurement policy, pharmaceutical companies are facing higher requirements. Companies that rely on generic drugs and me-too new drugs need to make timely adjustments. This means thatWhether large corporations or small R&D enterprises, all should strengthen their “internal capabilities” and prioritize product quality and the development of innovation capacity.”

Dr. Shou also pointed out that China’s new drug R&D industry still faces certain pain points, such as the continuous rise in R&D costs—particularly clinical trial costs—in recent years, and insufficient talent reserves and independent innovation capabilities within enterprises. These challenges are even more formidable for small pharmaceutical companies. “How to foster a sustainable ecosystem for innovative drug development remains a question worthy of careful consideration.”